Venom Immunotherapy: Questions and Controversies.

Allergens / immunology Anaphylaxis / etiology Animals Bites and Stings / complications Child Desensitization, Immunologic / adverse effects Epinephrine / therapeutic use Humans Hypersensitivity / complications Insecta Omalizumab / therapeutic use Venoms / immunology
Anaphylaxis Epinephrine Insect sting Venom allergy Venom immunotherapy

Journal

Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635

Informations de publication

Date de publication:
02 2020
Historique:
entrez: 26 11 2019
pubmed: 26 11 2019
medline: 2 6 2020
Statut: ppublish

Résumé

Questions and controversies regarding venom immunotherapy (VIT) remain. It is important to recognize risk factors for severe sting anaphylaxis that guide the recommendation for testing, epinephrine injectors, and VIT. Premedication, rush VIT, and omalizumab are successful in overcoming recurrent systemic reactions to VIT. A maintenance dose is adequate in children, but higher doses are needed in high-risk patients. The consensus on risk of β-blockers and angiotensin-converting enzyme inhibitors in patients on VIT has shifted to the belief that risk is small. The decision to stop VIT after 5 years rests on known risk factors rather than any diagnostic tests.

Identifiants

DOI: 10.1016/j.iac.2019.09.002 PMID: 31761121
pubmed: 31761121
pii: S0889-8561(19)30064-5
doi: 10.1016/j.iac.2019.09.002
pii:
doi:

Substances chimiques

Allergens 0
Venoms 0
Omalizumab 2P471X1Z11
Epinephrine YKH834O4BH

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-68

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

David B K Golden (DBK)

Department of Medicine, Division of Allergy-Immunology, Johns Hopkins University, 20 Crossroads Drive, Owings Mills, MD 21117, USA. Electronic address: dbkgolden@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Antigènes › Allergènes › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Anaphylaxie › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Eucaryotes › Animaux › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Plaies et blessures › Morsures et piqûres › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Désensibilisation immunologique › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Épinéphrine › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Eucaryotes › Animaux › Invertébrés › Arthropodes › Insectes › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Omalizumab › Venom Immunotherapy: Questions and Controversies.
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Venins › Venom Immunotherapy: Questions and Controversies.